Fluticasone Propionate/Salmeterol MDPI (AirDuo RespiClick®): A Review in Asthma
- 62 Downloads
The novel, easy-to-use, breath-actuated fluticasone propionate/salmeterol multidose dry powder inhaler (MDPI) (AirDuo RespiClick®) was recently approved in the USA for twice-daily treatment of asthma in patients aged ≥ 12 years. This inhaled corticosteroid (ICS) and long-acting β2-adrenoreceptor agonist (LABA) combination treatment is available in low-, mid- and high-dosage formulations (55/14, 113/14 and 232/14 μg, respectively). In 12-week, phase III trials in patients aged ≥ 12 years with persistent asthma, all three dosages of fluticasone propionate/salmeterol MDPI treatment produced significant improvements in lung function and other asthma symptoms compared with fluticasone propionate MDPI monotherapy or placebo MDPI. In a 26-week, phase III trial in this patient population, mid- and high-dosage fluticasone propionate/salmeterol MDPI were noninferior to mid- (250/50 μg) and high- (500/50 μg) dosage fluticasone propionate/salmeterol DPI (Advair Diskus®), respectively, in terms of improvements in lung function. Treatment-emergent adverse events (TEAEs) with fluticasone propionate/salmeterol MDPI were mostly of mild to moderate severity, with no severe TEAEs deemed to be treatment related. Although long-term pharmacovigilance is required to fully establish its safety, given the ease of use and favorable characteristics of the device and its clinical efficacy at relatively low metered doses of the active moieties, fluticasone propionate/salmeterol MDPI is an important emerging treatment option in patients aged ≥ 12 years with asthma.
During the peer review process, the manufacturer of fluticasone propionate/salmeterol MDPI was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Roy Pleasants is a speaker for AstraZeneca and has received grants and/or consulting fees or honoraria from GlaxoSmithKline and Boehringer Ingelheim. Julia Paik and Lesley Scott are salaried employees of Adis/Springer and declare no relevant conflicts of interest.
- 1.Global Initiative for Athma. Global strategy for asthma management and prevention (2017 update). 2017. www.ginasthma.org. Accessed 22 Feb 2018.
- 5.Lewis A, Torvinen S, Dekhuijzen PNR, et al. Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: the potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®. Respir Med. 2017;129:179–88.CrossRefPubMedGoogle Scholar
- 10.Jones R, Martin J, Thomas V, et al. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. Int J Chron Obstruct Pulmon Dis. 2017;12:2445–54.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Teva Respiratory LLC. AirDuo™ RespiClick®: US prescribing information. 2017. https://www.accessdata.fda.gov/. Accessed 22 Feb 2018.
- 13.US Center for Drug Evaluation and Research. Summary review (AirDuo RespiClick). 2017. https://www.accessdata.fda.gov/. Accessed 22 Feb 2018.
- 14.Raphael G, Yiu G, Sakov A, et al. Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older. J Asthma. 2017. https://doi.org/10.1080/02770903.2017.1350971.PubMedGoogle Scholar
- 17.Data on file, Teva Respiratory LLC, 2017.Google Scholar
- 21.GlaxoSmithKline. Advair Diskus®: prescribing information. 2017. https://www.accessdata.fda.gov/. Accessed 22 Feb 2018.
- 22.Nugent C, Yiu G, Song S, et al. The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma. J Asthma. 2017. https://doi.org/10.1080/02770903.2017.1373392.PubMedGoogle Scholar
- 31.US Food & Drug Administration. Long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS): Drug Safety Communication—boxed warning about asthma-related death removed. 2017. https://www.fda.gov/. Accessed 22 Feb 2018.